Collate announced a $95 million Series A funding round as the company continues building an AI-native platform designed for regulated workflows across the life sciences industry. The round was led by a group of investors that includes Redpoint Ventures, First Round Capital, CRV, Conviction, and Y Combinator. The company said the funding will support its mission of delivering trusted, patient-first artificial intelligence solutions for pharmaceutical and life sciences organizations.
Founded by CEO Surbhi Sarna, Collate provides GxP-compliant software designed to automate and streamline highly regulated workflows within life sciences organizations. The company focuses on helping customers deploy AI solutions without requiring extensive customization or lengthy implementation timelines.
According to Collate, many of the world’s largest life sciences companies are already using the platform to support regulated processes. The company differentiates itself through pre-built workflows created by a team with deep industry experience, reducing the burden on subject matter experts who would otherwise need to spend significant time training AI systems on life sciences-specific processes.
In addition to its out-of-the-box capabilities, Collate offers forward-deployed engineering resources and implementation teams to help customers tailor AI solutions to specialized use cases. The company’s long-term objective is to become a comprehensive end-to-end AI platform for the life sciences sector.
The funding comes as pharmaceutical, biotechnology, and healthcare organizations increasingly seek ways to apply artificial intelligence to highly regulated environments while maintaining compliance, quality standards, and patient safety requirements.
Collate plans to continue expanding its platform and capabilities as demand grows for AI tools capable of operating within complex regulatory frameworks across research, development, manufacturing, and other critical life sciences functions.
KEY QUOTES:
“We’re grateful that some of the largest life science companies in the world trust Collate with their regulated workflows. We deliver AI-native, GxP compliant software that executes the most time consuming tasks out-of-the-box. Your SMEs don’t need to spend their valuable time teaching us life science specific workflows, we spent years doing them ourselves.”
Surbhi Sarna, CEO And Founder, Collate
